BioSpace News Archive

BioLineRx Ltd., a late clinical-stage biopharmaceutical company focused on oncology, announced it will release its audited financial results for the year ended December 31, 2021 on Wednesday, March 16, 2022, before the US markets open.

Theseus Pharmaceuticals, Inc. announced business highlights and reported financial results for the fourth quarter and full year ended December 31, 2021.

BioCurity today announced the Company’s presentation at the American College of Radiation Oncology (ACRO) 2022 Summit on March 11, 2022, from 12:00-1:00pm EST at the Westin Fort Lauderdale Beach Resort in Fort Lauderdale, Florida.

Stoke Therapeutics, Inc. today reported financial results for the full year ended December 31, 2021 and provided business updates.

Albany NY, United States: The demand within the global biodegradable stents market is ascending at an exponential rate in recent times.

A laboratory peristaltic pumps allow fluids to be pumped through a flexible tube that is wrapped around a rotating roller in the pump head which squeezes the liquid out of the tube with compression force.

Surgical laser products are used in laser surgeries to destroy or cut abnormal or diseased tissues, destroy or shrink lesions and tumors, seal lymph vessels, remove moles and tattoos, and close off blood vessels and nerve endings among various other uses.

AlzeCure Pharma AB announced that the company is participating at the BioStock Investor Meeting on March 16 at 14:25 CET, where CEO Martin Jönsson will present the company’s latest developments, including the ongoing rights issue.

Abivax SA, a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, reports promising results from its phase 2a maintenance trial in rheumatoid arthritis after one year of continued daily treatment with 50mg ABX464.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced that the first subjects have been dosed in the company’s Phase 1, first-in-human trial of their clinical candidate CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor.